Neoplasms

All Conditions

Digestive System Diseases

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Adenocarcinoma

Pancreatic Neoplasms

Carcinoma, Pancreatic Ductal

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Gastrointestinal Agents

All Drugs and Chemicals

Pancrelipase

Pancreatin

Patients who received SOC and received IRE

Patients who received SOC and did not receive IRE

NanoKnife System

This multicenter, observational study will evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC). Eligible patients will be recruited over a 36-month period and participating institutions will enroll and provide data on consecutive patients that meet inclusion and exclusion criteria. Each patient will be followed up for the duration of the study or until death. The study will include two (2) cohorts: patients who received standard of care (SOC) and received irreversible electroporation (IRE) \[IRE cohort\], and patients who were treated with SOC and did not receive IRE \[SOC cohort\].

A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma

To evaluate the effectiveness of the NanoKnife System when used for the ablation of Stage 3 PC in real world treatment settings, by testing the hypothesis that IRE with the NanoKnife System improves overall survival (OS)

Angiodynamics, Inc.

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Symptoms and General Pathology

Prostatic Neoplasms

Disease Progression

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

SABR is delivered to all sites of oligometastasis with continuation of Enzalutamide. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in SOC Arm.

SABR

Three options:

1. Continuation of Enzalutamide
2. Observation
3. Switch to next line treatment

In this study, the investigator aim to evaluate the role of PMSA-PET guided SABR on progression free survival (PFS) in patients with oligoprogressive mCRPC with Enzalutamide. The potential improvement in PFS with SABR while continuing the initial-responding Enzalutamide is potentially benefiting to patients in terms of overall disease control.

Prostate PMSABR Study

PSMA-PET Guided Stereotactic Ablative Body Radiotherapy for Oligometastasis in Metastatic Castration-resistant Prostate Cancer (mCRPC) With Progression on Enzalutamide (PMSABR Study)

Darren Poon

Principal Investigator

MCED

GRAIL Customer Service

Lisa Hue

Adam Zoble

Kristen Lingle

Charlene Preys

Karen Smith

Charles Atwood

Jennifer D'Angelo

Ann Worthen

Pilkerton Courtney

REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 17,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand the real-world experience of Galleri® in clinical settings.

REFLECTION: A Clinical Practice Learning Program for Galleri®

REFLECTION: Real World Evidence for Learnings in Early Cancer Detection, a Clinical Practice Learning Program for Galleri®

GRAIL, LLC

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

Empowerment and Navigation

Yamile Molina, PhD

The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions with the study team across 3 consecutive weeks

The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions with the study team across 3 consecutive weeks. Sessions will be based on landline or cellphone calls. Within 1 week after each session, all Latina Aim 1 participants will receive copies of the multi-media materials (e.g., personalized plans) by text message or mail, depending on participants' preferences

Control Sessions will be as follows:

Session 1 Learning about Breast Cancer (BC) care uptake Targets the effects of Social Determinants of Heath (SDH) and genetic risk factors on Non-Latino White (NLW) Latino BC disparities Study staff will give personnel testimonials, empirical data and individual action plans behavior change and BC care uptake Session 2 Learning about Diet to promote BC prevention per the American Cancer Society (ACS) BC screening and prevention guidelines Session 3 Learning about Physical Activity to promote BC prevention

Empowerment and Navigation Sessions will be as follows:

Session 1 Learning about Breast Cancer (BC) care uptake Targets the effects of SDH and genetic risk factors on NLW/Latino BC disparities ACS BC screening and prevention guidelines Identify and address SDH and genetic risk factors Study staff will give personnel testimonials, empirical data and individual action plans for behavior change Session 2 Teaching about BC Targets the importance of sharing BC information and personal barriers \& preferred solutions to sharing BC information Study staff will give personnel testimonials and individual action plans for sharing information and role playing activities Session 3 Teaching about BC Targets opportunities \& skills in sharing BC information participants will give testimonials and relay empirical data. There will be a group discussion and plans for sharing information

There will be a post intervention BC survey call and an end of study BC survey call

Bicultural, bilingual study staff will engage participants in a 5-10 minute call/text every month to "check in" until the end of the study

Empowerment and navigation and Standard of Care (SOC) (Control)

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care

Number of participants that undergo risk-based BC screening per ACS guidelines versus the control group

Number of participants that undergo recommended genetic services versus the control group

University of Illinois at Chicago

Prinicipal Investigator

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer	NCT03899649	Stage III Pancr...	SOC NanoKnife Syste...	18 Years -	Angiodynamics, Inc.
Prostate PMSABR Study	NCT04742972	Prostate Cancer	SABR SOC	18 Years -	Chinese University of Hong Kong
REFLECTION: A Clinical Practice Learning Program for Galleri®	NCT05205967	Early Detection... Cancer	MCED SOC	22 Years -	GRAIL, LLC
Prostate PMSABR Study	NCT04742972	Prostate Cancer	SABR SOC	18 Years -	Chinese University of Hong Kong
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer	NCT03899649	Stage III Pancr...	SOC NanoKnife Syste...	18 Years -	Angiodynamics, Inc.
REFLECTION: A Clinical Practice Learning Program for Galleri®	NCT05205967	Early Detection... Cancer	MCED SOC	22 Years -	GRAIL, LLC
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care	NCT05483283	Breast Cancer	Empowerment and... SOC	30 Years -	University of Illinois at Chicago

Spots Global Cancer Trial Database for soc

Every month we try and update this database with for soc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for soc

Every month we try and update this database with for soc cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for soc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.